Cargando…

Novel infusion strategy reduces severe adverse events caused by the anti-GD2 monoclonal antibody naxitamab

INTRODUCTION: Anti-disialoganglioside 2 (anti-GD2) monoclonal antibodies (mAbs) are associated with Grade ≥3 (≥G3) adverse events (AEs) such as severe pain, hypotension, and bronchospasm. We developed a novel method of administering the GD2-binding mAb naxitamab, termed “Step-Up” infusion (STU), to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Varo, Amalia, Castañeda, Alicia, Chamorro, Saray, Muñoz, Juan Pablo, Gorostegui, Maite, Celma, Mónica S., Lopez, Sandra, Simao, Margarida, Perez-Jaume, Sara, Mora, Jaume
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196122/ https://www.ncbi.nlm.nih.gov/pubmed/37213300 http://dx.doi.org/10.3389/fonc.2023.1164949

Ejemplares similares

Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes
por: Muñoz, Juan Pablo, et al.
Publicado: (2023)

Naxitamab Combined with Granulocyte-Macrophage Colony-Stimulating Factor as Consolidation for High-Risk Neuroblastoma Patients in First Complete Remission under Compassionate Use—Updated Outcome Report
por: Mora, Jaume, et al.
Publicado: (2023)

The Role of Autologous Stem-Cell Transplantation in High-Risk Neuroblastoma Consolidated by anti-GD2 Immunotherapy. Results of Two Consecutive Studies
por: Mora, Jaume, et al.
Publicado: (2020)

How we approach the treatment of patients with high-risk neuroblastoma with naxitamab: experience from the Hospital Sant Joan de Déu in Barcelona, Spain
por: Castañeda, A., et al.
Publicado: (2022)

Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma
por: Mora, Jaume, et al.
Publicado: (2021)

Corrigendum to “How we approach the treatment of patients with high-risk neuroblastoma with naxitamab: experience from the Hospital Sant Joan de Déu in Barcelona, Spain”: [ESMO Open, 7 (2022) 100462]
por: Castañeda, A., et al.
Publicado: (2022)

Outpatient administration of naxitamab in combination with granulocyte‐macrophage colony‐stimulating factor in patients with refractory and/or relapsed high‐risk neuroblastoma: Management of adverse events
por: Mora, Jaume, et al.
Publicado: (2022)

Global Impact of Monoclonal Antibodies (mAbs) in Children: A Focus on Anti-GD2
por: Larrosa, Cristina, et al.
Publicado: (2023)

Naxitamab Activity in Neuroblastoma Cells Is Enhanced by Nanofenretinide and Nanospermidine
por: Galassi, Lucrezia, et al.
Publicado: (2023)

MRI investigation of glymphatic responses to Gd‐DTPA infusion rates
por: Ding, Guangliang, et al.
Publicado: (2018)

Targeting and killing glioblastoma with monoclonal antibody to O-acetyl GD2 ganglioside
por: Fleurence, Julien, et al.
Publicado: (2016)

Primed Infusion with Delayed Equilibrium of Gd.DTPA for Enhanced Imaging of Small Pulmonary Metastases
por: Kalber, Tammy L., et al.
Publicado: (2013)

Risk of adverse pregnancy outcomes prior to the onset of an autoimmune rheumatic disease: a systematic review
por: Muñoz, Candido Muñoz, et al.
Publicado: (2022)

Delivering Monoclonal Antibody Infusions to Novel Outpatient Settings
por: Minnich, Amy, et al.
Publicado: (2022)

GD3, a prominent ganglioside of human melanoma. Detection and characterisation by mouse monoclonal antibody
Publicado: (1982)

Editorial: Proceedings From the 4th Memorial Alicia Pueyo Workshop: “Moving Towards a Cure for Diffuse Intrinsic Pontine Glioma”
por: Mora, Jaume
Publicado: (2019)

Autologous Stem-Cell Transplantation for High-Risk Neuroblastoma: Historical and Critical Review
por: Mora, Jaume
Publicado: (2022)

A Monoclonal Antibody to O-Acetyl-GD2 Ganglioside and Not to GD2 Shows Potent Anti-Tumor Activity without Peripheral Nervous System Cross-Reactivity
por: Alvarez-Rueda, Nidia, et al.
Publicado: (2011)

Determining the Binding Affinity of Therapeutic Monoclonal Antibodies towards Their Native Unpurified Antigens in Human Serum
por: Bee, Christine, et al.
Publicado: (2013)

Clinical development methodology for infusion-related reactions with monoclonal antibodies
por: Doessegger, Lucette, et al.
Publicado: (2015)

The importance of early identification of infusion-related reactions to monoclonal antibodies
por: Cáceres, Macarena C, et al.
Publicado: (2019)

Structure Based Refinement of a Humanized Monoclonal Antibody That Targets Tumor Antigen Disialoganglioside GD2
por: Ahmed, Mahiuddin, et al.
Publicado: (2014)

Preparation and Evaluation of the Fully Humanized Monoclonal Antibody GD-mAb Against Respiratory Syncytial Virus
por: Tian, Puyuan, et al.
Publicado: (2019)

Comparison of canine ECV measurements derived from CMR: bolus injection vs. slow infusion of Gd-BOPTA
por: Hong, Kyungpyo, et al.
Publicado: (2014)

Prognostic value of patient‐derived xenograft engraftment in pediatric sarcomas
por: Castillo‐Ecija, Helena, et al.
Publicado: (2021)

Monoclonal antibodies as treatment for COVID-19
por: Medina Gamero, A., et al.
Publicado: (2022)

Acute bilateral angle closure induced by monoclonal antibody (Daratumumab) infusion
por: Saengsirinavin, Aim-on, et al.
Publicado: (2021)

Monoclonal Antibody Infusion Service for Obstetric Women Infected With COVID-19
por: Hiner, Jacqueline B., et al.
Publicado: (2022)

Acute low back pain as infusion-related reaction to monoclonal antibodies
por: Majenka, Pawel, et al.
Publicado: (2023)

Self-patterning Gd nano-fibers in Mg-Gd alloys
por: Li, Yangxin, et al.
Publicado: (2016)

Analysis of Adverse Events and Intravenous Iron Infusion Formulations in Adults With and Without Prior Infusion Reactions
por: Arastu, Asad H., et al.
Publicado: (2022)

Monoclonal antibody 3F8 recognises the neural cell adhesion molecule (NCAM) in addition to the ganglioside GD2.
por: Patel, K., et al.
Publicado: (1989)

Anti-Neuroblastoma Activity of Gold Nanorods Bound with GD2 Monoclonal Antibody under Near-Infrared Laser Irradiation
por: Peng, Ching-An, et al.
Publicado: (2011)

Optimized Expression, Purification of Herpes B Virus gD Protein in Escherichia coli, and Production of Its Monoclonal Antibodies
por: Jin, Zian, et al.
Publicado: (2016)

Digital TDPAC with rare earth isotope $^{169}$Yb, $^{147}$Gd, and $^{149}$Gd in Yb and Gd Doped CeO$_{2}$ and $^{147}$Gd in GdBa$_{2}$ Cu$_{3}$ O$_{7−\delta}$
por: Roeder, Jens, et al.
Publicado: (2011)

Long-term continuous infusion of anti-GD2 antibody CH14.18/CHO in relapsed/refractory neuroblastoma patients
por: Lode, Holger, et al.
Publicado: (2013)

Correspondence on "G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment" by Martinez Sanz et al
por: Mora, Jaume, et al.
Publicado: (2021)

Intratumoral co‐injection of NK cells and NKG2A‐neutralizing monoclonal antibodies
por: Melero, Ignacio, et al.
Publicado: (2023)

The effects of three different contrast agents (Gd-BOPTA, Gd-DTPA, and Gd-DOTA) on brachial plexus magnetic resonance imaging
por: Zhang, Xiaojing, et al.
Publicado: (2021)

LGG-29. Use of Bevacizumab in Pediatric Low-grade Glioma: Ten-year experience in a single center
por: Rafael, Margarida Simão, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kn22fct0a61u3325r2c8rouo2g